Thus, in these cases, everolimus was offered in combination with exemestane based on the BOLERO-2 phase 3 trial that led to the approval of this combination therapy for patients with advanced hormone-receptor-positive/HER2-negative breast cancer who progressed with prior nonsteroidal aromatase inhibitor therapy [10]. This evidence concerns the gene NR4A1 and breast carcinoma.